Pasithea Therapeutics Corporation Enters into At The Market Offering Agreement with H.C. Wainwright Co. LLC
| GNMSF Stock | USD 222.81 10.31 4.85% |
Roughly 54% of Genmab AS's stockholders are presently thinking to get in. The analysis of overall sentiment of trading Genmab AS pink sheet suggests that some investors are interested at this time. The current market sentiment, together with Genmab AS's historical and current headlines, can help investors time the market. In addition, many technical investors use Genmab AS stock news signals to limit their universe of possible portfolio assets.
Genmab AS pink sheet news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Genmab daily returns and investor perception about the current price of Genmab AS as well as its diversification or hedging effects on your existing portfolios.
Genmab |
On November 26, 2024, Pasithea Therapeutics Corp., a Delaware-based biopharmaceutical company, announced that it has entered into an At The Market Offering Agreement with H.C. Wainwright Co., LLC, acting as the Sales Agent. The agreement enables Pasithea Therapeutics to offer for sale its common stock, with a par value of 0.0001 per
Read at thelincolnianonline.com
 |
Genmab AS Fundamental Analysis
We analyze Genmab AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genmab AS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genmab AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Z Score
Z Score Comparative Analysis
Genmab AS is currently under evaluation in z score category among its peers. Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
Genmab AS Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Genmab AS pink sheet to make a market-neutral strategy. Peer analysis of Genmab AS could also be used in its relative valuation, which is a method of valuing Genmab AS by comparing valuation metrics with similar companies.
Peers
Genmab AS Related Equities
| PPBT | Purple Biotech | 150.00 | ||||
| SNPX | Synaptogenix | 8.68 | ||||
| LEGN | Legend Biotech | 2.95 | ||||
| DNLI | Denali Therapeutics | 2.52 | ||||
| SCPH | Scpharmaceuticals | 2.49 | ||||
| BPMC | Blueprint Medicines | 1.29 | ||||
| ALGS | Aligos Therapeutics | 0.82 | ||||
| ARGX | Argenx NV | 0.25 | ||||
| TPST | Tempest Therapeutics | 1.04 | ||||
| CANF | Can Fite | 1.36 | ||||
| CING | Cingulate | 1.38 | ||||
| XTLB | XTL Biopharmaceutica | 1.60 | ||||
| ASND | Ascendis Pharma | 1.89 | ||||
| BRTX | BioRestorative Therapies | 1.96 | ||||
| MNPR | Monopar Therapeutics | 2.31 | ||||
| CADL | Candel Therapeutics | 2.97 | ||||
| SABS | SAB Biotherapeutics | 3.77 | ||||
| KTTA | Pasithea Therapeutics | 3.88 | ||||
| IKT | Inhibikase Therapeutics | 5.48 | ||||
| DMAC | DiaMedica Therapeutics | 5.65 | ||||
| SRZN | Surrozen | 6.80 | ||||
| MOLN | Molecular Partners | 7.22 |
Complementary Tools for Genmab Pink Sheet analysis
When running Genmab AS's price analysis, check to measure Genmab AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab AS is operating at the current time. Most of Genmab AS's value examination focuses on studying past and present price action to predict the probability of Genmab AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab AS's price. Additionally, you may evaluate how the addition of Genmab AS to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |